Quality Control Tests Research Articles

Development and Validation of High-Performance Thin Layer Chromatographic Method for Simultaneous Estimation of Curcumin and Artemisinin

Curcumin and Artemisinin are proposed to be formulated as combination therapy to expand the antimalarial effect in resistant and liable isolates. The present research work was to develop and validate a simple, accurate, precise, high-performance thin layer chromatographic method for simultaneous determination of Curcumin and Artemisinin. The chromatographic separation was carried out on a precoated silica gel aluminum plate, 20 × 20 cm, 100μm thickness, with a mixture of Hexane, Toluene and Ethyl acetate (6:1:3) as mobile phase UV detection was performed at 496nm. The Rf were 0.23 and 0.76 for Curcumin and Artemisinin, respectively. Calibration plots were linear over the concentration range 200-1000ng/band for both Curcumin and Artemisinin. The method was validated in accordance with ICH Q2(R1) guidelines for linearity, sensitivity accuracy, precision, and robustness. The percent recoveries in terms of accuracy for the synthetic mixture were found to be 99.8% to 100.0% and 99.94% to 100.4%, and the pooled percent relative standard deviation for repeatability and intermediate precision studies was found to be 0.015-0.042% and 0.008-0.070% for Curcumin and Artemisinin, respectively. A factorial design was used to optimize the chromatographic conditions for the robustness study. In conclusion, a novel, simple, accurate and reproducible HPTLC method was developed and could be applied for quality control testing of Curcumin and Artemisinin in synthetic mixture.

Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial.

The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I). Herein, we aimed to establish a robust method for the manufacturing and quality control of [211At]NaAt solution for intravenous administration under the good manufacturing practice guidelines for investigational products to conduct an investigator-initiated clinical trial. 211At was separated and purified via dry distillation using irradiated Bi plates containing 211At obtained by the nuclear reaction of 209Bi(4He, 2n)211At. After purification, the 211At trapped in the cold trap was collected in a reaction vessel using 15 mL recovery solution (1% ascorbic acid and 2.3% sodium hydrogen carbonate). After stirring the 211At solution for 1h inside a closed system, the reaction solution was passed through a sterile 0.22μm filter placed in a Grade A controlled area and collected in a product vial to prepare the [211At]NaAt solution. According to the 3-lot tests, decay collected radioactivity and radiochemical yield of [211At]NaAt were 78.8 ± 6.0 MBq and 40 ± 3%, respectively. The radiochemical purity of [211At]At- obtained via ion-pair chromatography at the end of synthesis (EOS) was 97 ± 1%, and remained > 96% 6h after EOS; it was detected at a retention time (RT) 3.2-3.3min + RT of I-. LC-MS analysis indicated that this principal peak corresponded with an astatide ion (m/z = 210.988046). In gamma-ray spectrometry, the 211At-related peaks were identified (X-ray: 76.9, 79.3, 89.3, 89.8, and 92.3keV; γ-ray: 569.7 and 687.0keV), whereas the peak at 245.31keV derived from 210At was not detected during the 22h continuous measurement. The target material, Bi, was below the 9 ng/mL detection limit in all lots of the finished product. The pH of the [211At]NaAt solution was 7.9-8.6; the concentration of ascorbic acid was 9-10mg/mL. Other quality control tests, including endotoxin and sterility tests, confirmed that the [211At]NaAt solution met all quality standards. We successfully established a stable method of [211At]NaAt solution that can be administered to humans intravenously as an investigational product.

Quality assurance of SARS-CoV-2 testing laboratories during the pandemic period in India – An experience from a designated provider laboratory

PurposeIndian Council of Medical Research (ICMR) initiated an Inter-Laboratory Quality Control testing (ILQC) program for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing. Under this program, SARS-CoV-2 testing laboratories across the country submit specimens to the assigned State Quality Control (SQCs) laboratories for ILQC testing. This study aimed to investigate the performance of public and private SARS-CoV-2 testing laboratories in Delhi and highlights the country’s effort in ramping up testing facility with close monitoring of the quality of Covid-19 testing results. MethodsIn the present study, two-years of SARS-CoV-2 testing data is included. During July 2020 through February 2022, a total of 1791 anonymised specimens were received from 56 public and private laboratories. These specimens were processed by reverse transcriptase – polymerase chain reaction (RT-PCR) tests as per National Institute of Virology (NIV) protocol and the results were uploaded on the ICMR quality control/quality assurance (QC/QA) portal without directly conveying the results to respective participating laboratories. This portal generated a final report stating concordance and intimate results to individual laboratories. ResultsAmong the 1791 specimens, 25 were rejected and the remaining 1766 were tested. Among these specimens 1691 (95.75%) revealed concordance, and 75 (4.24%) were discordant. A total of 29 laboratories had 100% concordance, 21 laboratories had over 90% concordance and six laboratories had over 80% concordance. ConclusionsThe study demonstrates that the establishment of an inter-laboratory comparison program for SARS-CoV-2 testing helped in monitoring quality of SARS-CoV-2 testing in the country.

Innovative Reversed-Phase Chromatography Platform Approach for the Fast and Accurate Characterization of Membrane Vesicles' Protein Patterns.

Outer membrane vesicles (OMVs) have been widely explored to develop vaccine candidates for bacterial pathogens due to their ability to combine adjuvant properties with immunogenic activity. OMV expresses a variety of proteins and carbohydrate antigens on their surfaces. For this reason, there is an analytical need to thoroughly characterize the species expressed at their surface: we here present a simple and accurate reversed-phase ultrahigh-performance liquid chromatography (RP-UPLC) method developed according to quality by design principles. This work provides an analytical alternative to the classical sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) characterization. The higher selectivity and sensitivity of the RP-UHPLC assay allow for the identification of additional protein species with respect to SDS-PAGE and facilitate its precise relative abundance quantification. According to validation results, the assay showed high accuracy, linearity, precision, repeatability, and a limit of quantification of 1% for less abundant proteins. This performance paves the way for improved production campaign consistency while also being analytically simple (no sample pretreatment required), making it suitable for routine quality control testing. In addition, the applicability of the assay to a wider range of vesicle classes (GMMA) was demonstrated.

Comparative evaluation of some moxifloxacin hydrochloride tablet brands marketed in Nigeria using five different validated analytical methods

Background: Assay of pharmaceuticals is an important aspect of quality control. It is necessary to compare the bioequivalence of generic brands of the any drug to an innovator/comparator brand as this forms the basis for comparing their therapeutic equivalence.Objective: This study aimed to determine the most accurate method for the assay of moxifloxacin hydrochloride (MOX-HCl) tablet brands in Nigerian markets by using five different validated analytical methods and also verify their interchangeability.Material & Methods: This study involved three brands of MOX-HCl including the comparator brand, Moxiget®. The study involves both quality control tests including: weight uniformity, diameter, thickness, friability, hardness, disintegration, dissolution and content of active ingredient (assay) methods including: phosphate buffered UV-Vis spectrophotometric, UV spectrophotometric, kinetic spectrophotometric, colorimetry and utilization of oxidation-reduction reaction methods.Results: All the samples used for this study passed the quality control tests and thus were of standard quality and therefore pharmaceutically equivalent.Conclusion: This study therefore conclude that phosphate buffered UV-Vis spectrophotometry provide the most accurate method to assay Moxifloxacin tablet, colorimetry assay method can serve as a substitute to the preferred method for the moxifloxacin assay and the three samples assayed in this work are interchangeable with the comparator brand (Moxiget®).

Automated Web-based Software for CT Quality Control Testing of Low-contrast Detectability using Model Observers.

The Channelized Hotelling observer (CHO) is well correlated with human observer performance in many CT detection/classification tasks but has not been widely adopted in routine CT quality control and performance evaluation, mainly because of the lack of an easily available, efficient, and validated software tool. We developed a highly automated solution - CT image quality evaluation and Protocol Optimization (CTPro), a web-based software platform that includes CHO and other traditional image quality assessment tools such as modulation transfer function and noise power spectrum. This tool can allow easy access to the CHO for both the research and clinical community and enable efficient, accurate image quality evaluation without the need of installing additional software. Its application was demonstrated by comparing the low-contrast detectability on a clinical photon-counting-detector (PCD)-CT with a traditional energy-integrating-detector (EID)-CT, which showed UHR-T3D had 6.2% higher d' than EID-CT with IR (p = 0.047) and 4.1% lower d' without IR (p = 0.122).

Lessons learned from contamination with endotoxin originated from the supplement in the cell culture medium

IntroductionEndotoxin is a typical pyrogen derived from the outer membrane of Gram-negative bacteria. In fabricating cell-based medicinal products, it is necessary to control endotoxin in the process and the products. In the quality control tests of our clinical study, endotoxin concentration in the culture supernatant of autologous oral mucosal epithelial cell sheets exceeded the criterion value. Therefore, endotoxin measurements were conducted to clarify the cause of the endotoxin contamination. MethodsThe reagents used to prepare the culture medium, the unused culture medium, and the culture supernatants were diluted with pure water. Endotoxin concentrations in the diluted samples were measured. ResultsEndotoxin was detected in both the unused culture medium and the culture supernatant of the epithelial cell sheets at higher concentrations than the criterion value. Therefore, endotoxin concentrations in the reagents used to prepare the culture medium were measured and were found to be below the criterion value, except for cholera toxin. On the other hand, three lots of cholera toxin products were used for the measurement, and the endotoxin concentrations were higher than the criterion value. The results indicate that the endotoxin contamination is caused by the cholera toxin product. ConclusionsTo prevent endotoxin contamination in cell-based medicinal products, endotoxin concentrations in reagents used for the fabrication should be measured in the facility conducting clinical research or confirmed by an adequate certificate of analysis from the manufacturers of the reagents.

Validating human induced pluripotent stem cell-specific quality control tests for the release of an intermediate drug product in a Good Manufacturing Practice quality system

One of the challenges in Good Manufacturing Practice (GMP)-compliant human induced pluripotent stem cell (hiPSC) production is the validation of quality control (QC) tests specific for hiPSCs, which are required for GMP batch release. This study presents a comprehensive description of the validation process for hiPSC-specific GMP-compliant QC assays; more specifically, the validation of assays to assess the potential presence of residual episomal vectors (REVs), the expression of markers of the undifferentiated state and the directed differentiation potential of hiPSCs. Critical aspects and specific acceptance criteria were formulated in a validation plan prior to assay validation. Assay specificity, sensitivity and reproducibility were tested, and the equipment used for each assay was subjected to performance qualification. A minimum input of 20 000 cells (120 ng of genomic DNA) was defined for accurate determination of the presence of REVs. Furthermore, since vector loss in hiPSC lines is a passage-dependent process, we advocate screening for REVs between passages eight and 10, as testing at earlier passages might lead to unnecessary rejection of hiPSC lines. The cutoff value for assessment of markers of the undifferentiated state was set to the expression of at least three individual markers on at least 75% of the cells. When multi-color flow cytometry panels are used, a fluorescence minus one control is advised to ensure the control for fluorescent spread. For the assay to assess the directed differentiation potential, the detection limit was set to two of three positive lineage-specific markers for each of the three individual germ layers. All of our assays proved to be reproducible and specific. Our data demonstrate that our implemented analytical procedures are suitable as QC assays for the batch release of GMP-compliant hiPSCs.

How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?

This commentary responds to a case about diethylene glycol-contaminated glycerin in cough syrup. Glycerin is a commonly used excipient in medicines to improve texture and taste. Excipients are typically pharmacologically inactive ingredients contained in prescription and over-the-counter drugs that play a critical role in the delivery, effectiveness, and stability of active drug substances. The commentary first canvasses how contaminants enter the excipient supply chains. One way is by misleading labeling or intentional adulteration by manufacturers or suppliers. Another way is by human or systemic error. This commentary then discusses quality control testing and suggests the ethical and clinical importance of increased transparency in excipient supply chains.

Strength Properties and Sulphate Resistance of Self-Compacting Concrete Incorporating Silica Fume and Metakaolin

Abstract: Self-compacting concrete, or SCC, makes it possible to go over obstacles and get rid of vibration. Since 1988, SCC has been more and more well-liked in Japan, Europe, and the US due to the benefits it provides. SCC technology may reduce or perhaps completely eliminate concrete laying issues in difficult situations. Additionally, it reduces the number of times quality control tests need to be performed, saving time and effort. Quicker and less intricate in terms of placement and structure. When vibrating is not utilized, noise pollution is decreased. Concrete becomes more durable when SCC is used, particularly in parts with permeability defects or reinforcing congestion. The goal of this study is to look into how resistant self-compacting concrete made with metakaolin and silica fume is to sulfates and what its compressive and splitting tensile strengths are. Metakaolin and silica fume may also be used as cement substitutes at 5%, 10%, and 15% levels. The tests that are performed on the samples include sulfate, compressive resistance, and cracking tensile strength. On the seventh, 28th, and 56th days of life, a test is given. This experiment using self-compacting concrete from Metakolin and silica fume passed every plastic stage test with flying colors. Furthermore, the splitting tensile strength and hardened-stage compressive strength tests yielded good results. Comparing metakaolin with silica fume, the compressive strength increased by 15–45% and 18–38%, respectively. The use of metakaolin for cement and silica fume in the building process increased SCC's resistance to sulfate.

Formulation, Optimization and Evaluation of Solid SMEDDS of Pioglitazone

This investigation assessed 32 formulations of liquid self-microemulsifying drug delivery system (L-SMEDDS) for pioglitazone (PGZ). The optimal PLS12 formulation comprises 40% capmul MC8 (oil), 40% cremophore RH40 (surfactant), and 20% PEG (co-surfactant). PLS12 exhibited approximately 75 nm droplet size, below 200 nm, and a PDI of 0.47, indicating nanosized droplets with uniform distribution. The formulation demonstrated stability, and achieved supreme drug loading capacity. The enhanced L-SMEDDS was solidified into solidified SMEDDS utilizing Sylloid 244 FP, subsequently in a free-flowing powder without drug interactions. Tablets were successfully formulated by incorporating S-SMEDDS with diverse tableting excipients. The selected tablet batch passed quality control and stability tests. The tablet exhibited a rapid and pH-independent release profile. The combined impact of SMEDDS and tablets collectively enhanced the solubility and dissolution of PGZ hydrochloride

Experimental Behavior of a Steel Girder–Stringer–Floorbeam Bridge

The presented case study summarizes a quick-response project for the Tennessee Department of Transportation (TDOT), which focused on the steel-stringer behavior for a girder–stringer–floorbeam bridge. TDOT was confronted with relatively low stringer load ratings for many of their 31 similar structures. As a result, TDOT initiated this field study to ultimately produce refined load ratings. This information was then to be utilized for deciding whether an intervention (e.g., retrofit) was necessary. Diagnostic load testing was the approach selected and a representative bridge was chosen. Then load testing was comprehensively designed and executed. This included the installation of 42 strain gauges, data-acquisition quality-control testing, weighing and measuring test trucks, load testing of the structure, and then removal of the system. The load-test data provided insight into the true behavior of the bridge. The stringers were subjected to a combined interaction of the global and local response. Overall, the local demands were the largest component, but the magnitudes were well below the predicted values. This was partly because of the lateral distribution of the load. Additionally, partial composite action was identified between the steel stringers and concrete slab. Refined load ratings were calculated using the field-measured data and following the AASHTO Manual for Bridge Evaluation. The comparison of predicted to measured responses clearly indicated the conservative nature of the prior analytical calculations. The stringer load ratings were increased by 68% based on the field testing. In the end, the steel-stringer load ratings were sufficient, with no intervention necessary.

Evaluation of Quality and Antibacterial Activity of Four Brands of Ciprofloxacin Tablets Marketed in Libya

Ciprofloxacin is one of fluoroquinolones antibiotics used in treatment for infections of the urinary tract, skin and soft-tissues, and lower respiratory tract. There are many brands of ciprofloxacin tablets available in pharmacies of Albaiyda city and the aim of this study was to evaluate quality of four available brands of ciprofloxacin tablets by quality control parameters and to test their antibacterial activity. Four leading brands of ciprofloxacin tablet each with a label claim 500 mg were purchased from the various retail pharmacies of Albaiyda city and evaluated by in vitro quality control tests for tablet according to pharmacopeia (BP/ USP) that include evaluation of uniformity of weight and weight variation, friability, hardness, and disintegration time. The second evaluation was the antibacterial activity of the four brands against Klebsiella pneumonia, Staphylococcus aureus, and Escherichia coli by well diffusion susceptibility method. Weight variation for four brands of ciprofloxacin ranged from 0.507% to ,0.753%, the highest variation was found in Brand A, and the lowest weight variation was observed in Brand B and all brands comply with specification. Friability of all brands was below 1% which means that all brands have passed the test and met the specification, and the brand which most likely to be friable between brands is Brand B (0.64%) and the least likely to be friable is Brand C (0 %). The results indicated that all brands of ciprofloxacin tablets were not in the limit of hardness test and the highest hardness value was for Brand C (276 N), and the lowest hardness value was for Brand A (114.2 N). Disintegration time for four brands was under 5 minutes and all brands were complied with the both BP and USP specifications. larger zone of inhibition (ZI) for ciprofloxacin brands against Klebsiella pneumonia was found in Brand C (26.19mm) indicating that it has the highest activity and larger ZI for ciprofloxacin brands against Staphylococcus aureus was found in Brand D (40.40mm) and larger ZI for ciprofloxacin brands against Escherichia coli was also found in Brand D (21.21mm) indicating that it has the highest activity against both types of bacteria. From this study it was demonstrated that all four brands of ciprofloxacin tablet marketed in Libya comply with BP and USP specification for quality control test of uniformity of weight and weight variation, friability, and disintegration time, except that in hardness test in the four brands were found out the limit but this test is non compendial test and all the brands have similar antibacterial effect except Brand C which has slightly better microbiological activity against Klebsiella pneumonia and Brand D which is more effective against Staphylococcus aureus, and Escherichia coli.

Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.

Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other. The potency assay employs quantitative Reverse Transcription PCR (RT-Q-PCR) to quantitatively measure the transcripts from the four transgenes encoded by each product in in vitro infected cells, enabling simultaneous detection. Results showcase the assay's robustness and biological relevance, as it effectively detects potency loss in one component of the mixture comparably to in vivo immunogenicity testing. This report details the assay's setup and validation, offering valuable insights for the clinical development of similar genetic vaccines, particularly those encoding synthetic polypeptides.

Strategic Oversight and Quality Validation in Spice Production Enhancement

This study examines the effectiveness of a comprehensive control management and quality control system in the seasoning production process, focusing specifically on a menu-specific seasoning variant (MSS). The methodology encompassed various stages including material acceptance, sieving, mixing, and final packaging, integrated with stringent control measures such as equipment and facility cleaning, material separation, and machine maintenance. Quality control tests conducted included sodium chloride content, pH analysis, seal strength, and bubble tests. Results indicate that these systematic processes significantly enhance product quality by ensuring compliance with predefined quality standards. The implications of this study suggest that rigorous process oversight and detailed quality assessments can markedly improve the reliability and safety of food seasoning products, providing a framework for industry-wide best practices. Highlights: Process Management: Systematic control measures, including equipment and facility cleaning, ensure a contamination-free production environment. Quality Control: Rigorous testing, including sodium chloride content and pH analysis, guarantees that the products meet established quality and safety standards. Product Compliance: Implementation of advanced control and quality assurance protocols ensures that products consistently comply with industry standards. Keywords: Instant Seasoning, Quality Control, Safety Standards

A statistical approach to system suitability testing for mass spectrometry imaging.

Mass spectrometry imaging (MSI) elevates the power of conventional mass spectrometry (MS) to multidimensional space, elucidating both chemical composition and localization. However, the field lacks any robust quality control (QC) and/or system suitability testing (SST) protocols to monitor inconsistencies during data acquisition, both of which are integral to ensure the validity of experimental results. To satisfy this demand in the community, we propose an adaptable QC/SST approach with five analyte options amendable to various ionization MSI platforms (e.g., desorption electrospray ionization, matrix-assisted laser desorption/ionization [MALDI], MALDI-2, and infrared matrix-assisted laser desorption electrospray ionization [IR-MALDESI]). A novel QC mix was sprayed across glass slides to collect QC/SST regions-of-interest (ROIs). Data were collected under optimal conditions and on a compromised instrument to construct and refine the principal component analysis (PCA) model in R. Metrics, including mass measurement accuracy and spectral accuracy, were evaluated, yielding an individual suitability score for each compound. The average of these scores is utilized to inform if troubleshooting is necessary. The PCA-based SST model was applied to data collected when the instrument was compromised. The resultant SST scores were used to determine a statistically significant threshold, which was defined as 0.93 for IR-MALDESI-MSI analyses. This minimizes the type-I error rate, where the QC/SST would report the platform to be in working condition when cleaning is actually necessary. Further, data scored after a partial cleaning demonstrate the importance of QC and frequent full instrument cleaning. This study is the starting point for addressing an important issue and will undergo future development to improve the efficiency of the protocol. Ultimately, this work is the first of its kind and proposes this approach as a proof of concept to develop and implement universal QC/SST protocols for a variety of MSI platforms.

A validated extraction technique followed by high‐performance liquid chromatography‐ultraviolet analysis for the assay of melittin as an indicator component of honey bee venom in cosmeceutical products

AbstractHoney bee venom (HBV) is a valuable bee product famous for its therapeutic efficacy. HBV has a complex matrix containing several compounds, of which melittin is identified as the major component and can be considered an indicator compound. According to the numerous pharmacological effects of HBV, it can be a great candidate as an efficient active pharmaceutical ingredient (API). Despite the widespread analysis of crude HBV, not enough evaluations have been conducted on HBV pharmaceutical products, which is crucial in quality control procedures. Following the importance of APIs assay, we aimed to develop a feasible and valid HBV extraction method from cosmeceutical creams using precipitation techniques, and an analysis method was developed and validated based on high‐performance liquid chromatography.The analysis was well performed with a high separation capability. The method was repeatable and accurate and exhibited a linear behavior in melittin's 0.1–1.4 mg/mL concentration range. Accordingly, the extraction method revealed a notable recovery between 86% and 104%, and a 0.007 mg/mL detection limit and 0.022 mg/mL limit of quantification were estimated, respectively.Consequently, both extraction and analysis methods were considered valid and feasible, which may influence the quality control tests of HBV pharmaceutical and cosmetic products.

Automated radiosynthesis of [18F]DPA-714 on a commercially available IBA Synthera®

The goal of this work was to develop a reliable method to produce the well-validated microglial activation PET tracer, [18F]DPA-714, routinely for clinical and preclinical research using an IBA Synthera®. Optimization of literature methods included reduced precursor mass and use of TBA HCO3 as the phase transfer agent in place of Kryptofix® 222 in a 65-min synthesis with an average activity yield of 24.6 ± 3.8% (n = 5). Successful quality control testing and process validation results are reported.

Artificial intelligence in medicine: mitigating risks and maximizing benefits via quality assurance, quality control, and acceptance testing.

The adoption of artificial intelligence (AI) tools in medicine poses challenges to existing clinical workflows. This commentary discusses the necessity of context-specific quality assurance (QA), emphasizing the need for robust QA measures with quality control (QC) procedures that encompass (1) acceptance testing (AT) before clinical use, (2) continuous QC monitoring, and (3) adequate user training. The discussion also covers essential components of AT and QA, illustrated with real-world examples. We also highlight what we see as the shared responsibility of manufacturers or vendors, regulators, healthcare systems, medical physicists, and clinicians to enact appropriate testing and oversight to ensure a safe and equitable transformation of medicine through AI.

First implementation of quality control procedures on selected X-ray machines in South of Benin

Abstract Introduction: The use of X-ray equipment for medical diagnostic radiography procedures has increased due to advances and complexity of radiological procedures. Achieving good image quality while keeping exposure of workers, public and patient exposure to an acceptable level has become a prerequisite for the radiology department in order to comply with best international practices. The aim of this study was to undertake quality control measurement of seven (7) diagnostic radiography equipment in the south of Benin, the first of its kind. Material and methods: Multifunction detector (Piranha) and beam alignment test tool were used to perform quality control tests on seven (7) X-ray units. The method used as well as the interpretation of the results was based on the American Association of Physicists in Medicine (AAPM), United States Food and Drug Administration (FDA), Healing Arts Radiation Protection (HARP), Institute of Physics and Engineering in Medicine (IPEM), International Atomic Energy Agency (IAEA) and Canadian Safety code 35 (S.C 35) recommendations. Results: The quality control results showed that all X-ray equipment investigated were within standard limits for accuracy of exposure time below 10 ms; reproducibility of kVp, exposure time and dose output; specific dose-kVp2 linearity; and specific dose-mAs linearity. Five (5) out of seven (7) diagnostic X-ray machines passed quality control tests such as X-ray beam alignment, exposure time above 10 ms and kVp accuracy. One (1) X-ray machine failed the quality control test of beam filtration at 70 kVp and above. Conclusions: The findings of this study have provided baseline data for other radiology departments to embark on similar QA/QC activities, and also explore options for optimization of patient dose. However, there is a need to extend the study to cover more diagnostic X-ray machines throughout the country. It is anticipated that this would ultimately assist in improving radiation protection and safety during medical diagnostic radiological procedures.